Acumen Pharmaceuticals (Acumen Pharmaceuticals) EBIT : $-52.53 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals EBIT?

Acumen Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-13.87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-52.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Acumen Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 was -123.59%. Acumen Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -11,406.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Acumen Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 78.25%.

Acumen Pharmaceuticals EBIT Historical Data

The historical data trend for Acumen Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acumen Pharmaceuticals EBIT Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-7.81

-7.91

-19.58

-42.86

-51.79

Acumen Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial													-11.31	-13.48	-16.04	-9.14	-13.87

Competitive Comparison of Acumen Pharmaceuticals's EBIT

For the Biotechnology subindustry, Acumen Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's EV-to-EBIT falls into.

Acumen Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.53 Mil.

Acumen Pharmaceuticals (NAS:ABOS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Acumen Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-71.096 * ( 1 - 0% )	/	( (68.28	+	46.773)	/ 2 )
=	-71.096	/	57.5265
=	-123.59 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	310.125	-	8.201	-	( 243.522	-	max(0, 12.971	-	246.615	+	243.522	))
=	68.28

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	300.967	-	6.835	-	( 252.512	-	max(0, 8.472	-	255.831	+	252.512	))
=	46.773

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Acumen Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-55.492	/	( ( (0.503 + max(-9.237, 0))	+	(0.47 + max(-5.221, 0)) )	/	2 )
=	-55.492	/	( ( 0.503	+	0.47 )	/	2 )
=	-55.492	/	0.4865
=	-11,406.37 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.868)	-	(8.201	+	0	+	3.904)
=	-9.237

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.13)	-	(6.835	+	0	+	1.516)
=	-5.221

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Acumen Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-52.528	/	-67.131
	=	78.25 %

Acumen Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

427 Park Street, Charlottesville, VA, USA, 22902

Website

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Executives

Daniel Joseph Oconnell	director, officer: President and CEO	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner	officer: Chief Legal Office & Corp Sec	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers	officer: Chief Medical Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton	officer: Chief Operating Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga	officer: Chief Financial Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p.	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209